Physician profile
James Zinman
NPI 1578591467
$10,753.88
in general payments reported to CMS, 2019-2025
30 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $944 · 2020: $621 · 2021: $2,381 · 2022: $4,311 · 2023: $1,058 · 2024: $1,010 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529 · Travel and Lodging: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.52 |
| Travel and Lodging | $968.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $4,246.75 | 2020-2022 | |
| Coloplast Corp | $1,614.62 | 2019-2024 | Titan |
| Bayer Healthcare Pharmaceuticals INC. | $1,194.16 | 2019-2022 | |
| Antares Pharma, INC. | $932.45 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $680.13 | 2019-2021 | |
| Boston Scientific Corporation | $351.67 | 2019-2023 | Rezum Generator |
| Procept Biorobotics Corporation | $210.12 | 2019-2023 | Aquabeam Robotic System |
| Neotract INC. | $183.56 | 2019 | |
| Janssen Biotech, INC. | $182.03 | 2020-2025 | Rybrevant, Carvykti |
| Olympus America INC. | $165.37 | 2020-2025 | Itind System |
| Endo Pharmaceuticals INC. | $150.65 | 2019-2022 | |
| Pfizer INC. | $128.96 | 2019-2021 | |
| Clarus Therapeutics INC. | $111.06 | 2021 | |
| Myovant Sciences INC. | $97.07 | 2021 | |
| Allergan, INC. | $80.68 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $58.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $47.24 | 2020 | |
| Ferring Pharmaceuticals INC. | $46.66 | 2019-2024 | Adstiladrin |
| Zyla Life Sciences, INC. | $42.49 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $39.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $31.30 | 2021-2025 | Keytruda Qlex, Keytruda |
| Amgen INC. | $27.57 | 2019 | |
| Halozyme INC | $22.77 | 2023 | |
| 180 Medical, INC. | $22.28 | 2021 | |
| Seapearl East, INC | $19.07 | 2023 | |
| Tolmar, INC. | $16.68 | 2025 | Jatenzo, Eligard |
| Urovant Sciences INC | $14.53 | 2021 | |
| Aytu Biopharma, INC. | $12.38 | 2020 | |
| Avadel Specialty Pharmaceuticals, LLC | $11.89 | 2019 | |
| Verity Pharmaceuticals INC. | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Zinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.